Version 1
: Received: 26 February 2024 / Approved: 26 February 2024 / Online: 26 February 2024 (14:17:32 CET)
How to cite:
Proietti, I.; Battilotti, C.; Svara, F.; Innocenzi, C.; Spagnoli, A.; Potenza, C. Efficacy and Tolerability of a Microneedling Device plus Exosomes for Treating melasma. Preprints2024, 2024021458. https://doi.org/10.20944/preprints202402.1458.v1
Proietti, I.; Battilotti, C.; Svara, F.; Innocenzi, C.; Spagnoli, A.; Potenza, C. Efficacy and Tolerability of a Microneedling Device plus Exosomes for Treating melasma. Preprints 2024, 2024021458. https://doi.org/10.20944/preprints202402.1458.v1
Proietti, I.; Battilotti, C.; Svara, F.; Innocenzi, C.; Spagnoli, A.; Potenza, C. Efficacy and Tolerability of a Microneedling Device plus Exosomes for Treating melasma. Preprints2024, 2024021458. https://doi.org/10.20944/preprints202402.1458.v1
APA Style
Proietti, I., Battilotti, C., Svara, F., Innocenzi, C., Spagnoli, A., & Potenza, C. (2024). Efficacy and Tolerability of a Microneedling Device plus Exosomes for Treating melasma. Preprints. https://doi.org/10.20944/preprints202402.1458.v1
Chicago/Turabian Style
Proietti, I., Alessandra Spagnoli and Concetta Potenza. 2024 "Efficacy and Tolerability of a Microneedling Device plus Exosomes for Treating melasma" Preprints. https://doi.org/10.20944/preprints202402.1458.v1
Abstract
Melasma is a challenging skin condition which involves both structural and functional skin alterations. Despite the availability of various treatment options, the management remains complex. This is the first study to investigate topical application of Rosa Damascena stem cell exosomes when used concomitantly with microneedling in women and men with facial melasma. We recruited 20 subjects with Fitzpatrick skin types I-III, exhibiting melasma of varying severity. The modified Melasma Area and Severity Index (mMASI) and Global Aesthetic Improvement Scale (GAIS) were utilized to evaluate treatment response. The treatment protocol involved microneedling followed by exosome application over four or five sessions, at 4-week intervals. Ninety percent of subjects demonstrated a significant improvement in mMASI scores, while only 10% showed no change. GAIS assessment further supports overall improvement, with just 10% categorized as "not changed". Tolerability was favorable, with mild, transient side effects. Our findings suggest promising outcomes with this combined therapy, underscoring its potential as a safe and effective approach for treating melasma, particularly in severe and moderate cases. However, further research with larger sample sizes and control arms is warranted to validate these findings and explore long-term efficacy.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
